Simplex Trading’s Revance Therapeutics, Inc. RVNC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-38,598
Closed -$117K 10006
2024
Q4
$117K Buy
38,598
+14,220
+58% +$61.9K ﹤0.01% 5043
2024
Q3
$126K Sell
24,378
-33,744
-58% -$168K ﹤0.01% 4999
2024
Q2
$149K Buy
+58,122
New +$198K ﹤0.01% 4942
2023
Q4
Sell
-18,980
Closed -$156K 10070
2023
Q3
$217K Buy
18,980
+2,615
+16% +$50.3K ﹤0.01% 4254
2023
Q2
$414K Buy
16,365
+784
+5% +$24.4K ﹤0.01% 3509
2023
Q1
$501K Buy
15,581
+2,260
+17% +$70.5K ﹤0.01% 3264
2022
Q4
$245K Sell
13,321
-34,280
-72% -$784K ﹤0.01% 3980
2022
Q3
$1.28M Buy
47,601
+31,375
+193% +$636K ﹤0.01% 2369
2022
Q2
$224K Sell
16,226
-11,628
-42% -$179K ﹤0.01% 4470
2022
Q1
$543K Buy
+27,854
New +$422K ﹤0.01% 3747
2021
Q2
Sell
-3,047
Closed -$87.9K 10855
2021
Q1
$85K Sell
3,047
-3,545
-54% -$98.1K ﹤0.01% 5964
2020
Q4
$186K Sell
6,592
-1,098
-14% -$28.4K ﹤0.01% 4714
2020
Q3
$193K Buy
+7,690
New +$202K ﹤0.01% 4162
2020
Q1
Sell
-8,814
Closed -$182K 8429
2019
Q4
$143K Buy
8,814
+5,302
+151% +$82.2K ﹤0.01% 4113
2019
Q3
$45K Sell
3,512
-71
-2% -$869 ﹤0.01% 5125
2019
Q2
$46K Buy
+3,583
New +$45.2K ﹤0.01% 4931
2018
Q4
Sell
-1,897
Closed -$41.8K 7973
2018
Q3
$47K Sell
1,897
-154
-8% -$4.19K ﹤0.01% 5233
2018
Q2
$56K Sell
2,051
-276
-12% -$8.29K ﹤0.01% 4938
2018
Q1
$71K Buy
+2,327
New +$74.9K ﹤0.01% 2087
2017
Q4
Sell
-4,559
Closed -$131K 6847
2017
Q3
$125K Sell
4,559
-1,127
-20% -$27.3K 0.01% 1529
2017
Q2
$150K Sell
5,686
-1,865
-25% -$41.6K 0.01% 1422
2017
Q1
$157K Buy
+7,551
New +$155K 0.01% 1402
2016
Q3
Sell
-694
Closed -$10.1K 6586
2016
Q2
$9K Buy
+694
New +$12.3K ﹤0.01% 3720
2016
Q1
Sell
-17,365
Closed -$593K 6393
2015
Q4
$593K Buy
17,365
+8,300
+92% +$288K 0.05% 366
2015
Q3
$269K Buy
+9,065
New +$275K 0.02% 747

Other funds holding RVNC

Simplex Trading's RVNC Position: Q1 2025 in Review

Simplex Trading sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 38,598 shares — an estimated $117K sold.

Simplex Trading first reported a position in RVNC in Q3 2015 and held it in 25 quarters. The position peaked at $1.28M in Q3 2022. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • Simplex Trading reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • Simplex Trading sold 38,598 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $117K.
  • Simplex Trading first reported a position in Revance Therapeutics, Inc. in Q3 2015 and held it in 25 quarters.
  • Simplex Trading's Revance Therapeutics, Inc. position peaked at $1.28M in Q3 2022.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Simplex Trading's 13F filing for Q1 2025, filed 12 May 2025.